Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 82 articles:
HTML format



Single Articles


    October 2021
  1. GAMPER EM, Musoro JZ, Coens C, Stelmes JJ, et al
    Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials.
    BMC Cancer. 2021;21:1083.
    PubMed     Abstract available


    September 2021
  2. JAHNEN M, Mynzak E, Meissner VH, Schiele S, et al
    Diversity of cancer-related identities in long-term prostate cancer survivors after radical prostatectomy.
    BMC Cancer. 2021;21:1041.
    PubMed     Abstract available


  3. SHIINA M, Hashimoto Y, Kulkarni P, Dasgupta P, et al
    Role of miR-182/PDCD4 axis in aggressive behavior of prostate cancer in the African Americans.
    BMC Cancer. 2021;21:1028.
    PubMed     Abstract available


  4. LI Q, Xiao M, Shi Y, Hu J, et al
    eIF5B regulates the expression of PD-L1 in prostate cancer cells by interacting with Wig1.
    BMC Cancer. 2021;21:1022.
    PubMed     Abstract available


  5. SHARMA D, Osapoetra LO, Faltyn M, Giles A, et al
    In vivo assessment of prostate cancer response using quantitative ultrasound characterization of ultrasonic scattering properties.
    BMC Cancer. 2021;21:991.
    PubMed     Abstract available


    August 2021
  6. ANDKHOIE M, Szafron M
    Geographic disparities in Saskatchewan prostate cancer incidence and its association with physician density: analysis using Bayesian models.
    BMC Cancer. 2021;21:948.
    PubMed     Abstract available


  7. NAHAND JS, Khanaliha K, Mirzaei H, Moghoofei M, et al
    Possible role of HPV/EBV coinfection in anoikis resistance and development in prostate cancer.
    BMC Cancer. 2021;21:926.
    PubMed     Abstract available


  8. YANG Z, Ni Y, Zhao D, Zhang Y, et al
    Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone.
    BMC Cancer. 2021;21:919.
    PubMed     Abstract available


  9. ORTIZ-OTERO N, Marshall JR, Glenn A, Matloubieh J, et al
    TRAIL-coated leukocytes to kill circulating tumor cells in the flowing blood from prostate cancer patients.
    BMC Cancer. 2021;21:898.
    PubMed     Abstract available


    July 2021
  10. IMADA EL, Sanchez DF, Dinalankara W, Vidotto T, et al
    Transcriptional landscape of PTEN loss in primary prostate cancer.
    BMC Cancer. 2021;21:856.
    PubMed     Abstract available


  11. MANGIOLA S, McCoy P, Modrak M, Souza-Fonseca-Guimaraes F, et al
    Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression.
    BMC Cancer. 2021;21:846.
    PubMed     Abstract available


    June 2021
  12. CHONG W, Zhang Z, Luo R, Gu J, et al
    Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.
    BMC Cancer. 2021;21:655.
    PubMed     Abstract available


    May 2021
  13. ELLIS SD, Hwang S, Morrow E, Kimminau KS, et al
    Perceived barriers to the adoption of active surveillance in low-risk prostate cancer: a qualitative analysis of community and academic urologists.
    BMC Cancer. 2021;21:649.
    PubMed     Abstract available


  14. OKAMOTO T, Noro D, Hatakeyama S, Narita S, et al
    Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study.
    BMC Cancer. 2021;21:605.
    PubMed     Abstract available


  15. SHAH S, Beckmann K, Van Hemelrijck M, Challacombe B, et al
    Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.
    BMC Cancer. 2021;21:573.
    PubMed     Abstract available


  16. MA TM, Lamb JM, Casado M, Wang X, et al
    Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    BMC Cancer. 2021;21:538.
    PubMed     Abstract available


  17. CALAIS J, Zhu S, Hirmas N, Eiber M, et al
    Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
    BMC Cancer. 2021;21:512.
    PubMed     Abstract available


  18. AHETO JMK, Utuama OA, Dagne GA
    Geospatial analysis, web-based mapping and determinants of prostate cancer incidence in Georgia counties: evidence from the 2012-2016 SEER data.
    BMC Cancer. 2021;21:508.
    PubMed     Abstract available


  19. TAKESHIMA Y, Yamada Y, Teshima T, Fujimura T, et al
    Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy.
    BMC Cancer. 2021;21:501.
    PubMed     Abstract available


    April 2021
  20. LEE J, Yang SW, Jin L, Lee CL, et al
    Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
    BMC Cancer. 2021;21:472.
    PubMed     Abstract available


  21. WATANABE D, Kimura T, Watanabe K, Takano H, et al
    Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis.
    BMC Cancer. 2021;21:422.
    PubMed     Abstract available


  22. LIN H, Liu Q, Zeng X, Yu W, et al
    Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study.
    BMC Cancer. 2021;21:399.
    PubMed     Abstract available


  23. NGUYEN HTN, Xue H, Firlej V, Ponty Y, et al
    Reference-free transcriptome signatures for prostate cancer prognosis.
    BMC Cancer. 2021;21:394.
    PubMed     Abstract available


    March 2021
  24. WIND A, Hartman ED, Van Eekeren RRJP, Wijn RPWF, et al
    Validating a generic cancer consumer quality index in eight European countries, patient reported experiences and the influence of cultural differences.
    BMC Cancer. 2021;21:231.
    PubMed     Abstract available


  25. WONG SK, Hamm J, Shokoohi A, McGahan CE, et al
    Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment.
    BMC Cancer. 2021;21:215.
    PubMed     Abstract available


    February 2021
  26. KIM B, Jung S, Kim H, Kwon JO, et al
    The role of S100A4 for bone metastasis in prostate cancer cells.
    BMC Cancer. 2021;21:137.
    PubMed     Abstract available


  27. MARCELLUS KA, Crawford Parks TE, Almasi S, Jasmin BJ, et al
    Distinct roles for the RNA-binding protein Staufen1 in prostate cancer.
    BMC Cancer. 2021;21:120.
    PubMed     Abstract available


  28. THUREAU S, Marchesi V, Vieillard MH, Perrier L, et al
    Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase II
    BMC Cancer. 2021;21:117.
    PubMed     Abstract available


    January 2021
  29. MEUNIER ME, Blanchet P, Neuzillet Y, Lebret T, et al
    A review of new hormonal therapies for prostate cancer in black men: is there enough data?
    BMC Cancer. 2021;21:61.
    PubMed     Abstract available


  30. ZHANG PF, Xie D, Li Q
    Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance.
    BMC Cancer. 2021;21:35.
    PubMed     Abstract available


  31. WU L, Quan W, Yue G, Luo Q, et al
    Identification of a novel six autophagy-related genes signature for the prognostic and a miRNA-related autophagy predictor for anti-PD-1 therapy responses in prostate cancer.
    BMC Cancer. 2021;21:15.
    PubMed     Abstract available


    December 2020
  32. FREYTAG M, Kluth M, Bady E, Hube-Magg C, et al
    Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer.
    BMC Cancer. 2020;20:1220.
    PubMed     Abstract available


  33. LUND ME, Howard CB, Thurecht KJ, Campbell DH, et al
    A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
    BMC Cancer. 2020;20:1214.
    PubMed     Abstract available


  34. DODLA P, Bhoopalan V, Khoo SK, Miranti C, et al
    Gene expression analysis of human prostate cell lines with and without tumor metastasis suppressor CD82.
    BMC Cancer. 2020;20:1211.
    PubMed     Abstract available


    November 2020
  35. HERNANDEZ VARGAS JA, Ramirez Barbosa PX, Gil Quijano AM, Valbuena AM, et al
    Patterns of breast, prostate and cervical cancer incidence and mortality in Colombia: an administrative registry data analysis.
    BMC Cancer. 2020;20:1097.
    PubMed     Abstract available


    October 2020
  36. MENG Y, Hu X, Li S, Zeng X, et al
    miR-203 inhibits cell proliferation and ERK pathway in prostate cancer by targeting IRS-1.
    BMC Cancer. 2020;20:1028.
    PubMed     Abstract available


  37. MENDEZ LC, Arifin AJ, Bauman GS, Velker VM, et al
    Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial.
    BMC Cancer. 2020;20:978.
    PubMed     Abstract available


  38. SANGHERA S, Mohiuddin S, Coast J, Garfield K, et al
    Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.
    BMC Cancer. 2020;20:971.
    PubMed     Abstract available


  39. KAMDAR S, Fleshner NE, Bapat B
    A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence.
    BMC Cancer. 2020;20:953.
    PubMed     Abstract available


    September 2020
  40. KAWAHARA T, Kato M, Tabata K, Kojima I, et al
    A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment.
    BMC Cancer. 2020;20:919.
    PubMed     Abstract available


  41. WANG Y, Dong X, Qu Z, Peng K, et al
    Correlation between peripheral blood neutrophil-lymphocyte ratio and CD34 expression in prostate cancer.
    BMC Cancer. 2020;20:900.
    PubMed     Abstract available


  42. ANG M, Borg M, O'Callaghan ME
    Survival outcomes in men with a positive family history of prostate cancer: a registry based study.
    BMC Cancer. 2020;20:894.
    PubMed     Abstract available


  43. PRIVE BM, Janssen MJR, van Oort IM, Muselaers CHJ, et al
    Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
    BMC Cancer. 2020;20:884.
    PubMed     Abstract available


    August 2020
  44. CARIO CL, Chen E, Leong L, Emami NC, et al
    A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer.
    BMC Cancer. 2020;20:820.
    PubMed     Abstract available


  45. IGARASHI K, Yui Y, Watanabe K, Kumai J, et al
    Molecular evidence of IGFBP-3 dependent and independent VD3 action and its nonlinear response on IGFBP-3 induction in prostate cancer cells.
    BMC Cancer. 2020;20:802.
    PubMed     Abstract available


  46. HOUEDE N, Rebillard X, Bouvet S, Kabani S, et al
    Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study.
    BMC Cancer. 2020;20:757.
    PubMed     Abstract available


  47. CHEN J, Liu X, Ke K, Zou J, et al
    LINC00992 contributes to the oncogenic phenotypes in prostate cancer via targeting miR-3935 and augmenting GOLM1 expression.
    BMC Cancer. 2020;20:749.
    PubMed     Abstract available


  48. JAMIESON L, Forster MD, Zaki K, Mithra S, et al
    Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study.
    BMC Cancer. 2020;20:743.
    PubMed     Abstract available


  49. DONSWIJK ML, van Leeuwen PJ, Vegt E, Cheung Z, et al
    Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
    BMC Cancer. 2020;20:723.
    PubMed     Abstract available


    July 2020
  50. MATSUYAMA H, Matsubara N, Kazama H, Seto T, et al
    Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m(2)) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study.
    BMC Cancer. 2020;20:649.
    PubMed     Abstract available


  51. WOLLERSHEIM BM, van Asselt KM, van der Poel HG, van Weert HCPM, et al
    Design of the PROstate cancer follow-up care in Secondary and Primary hEalth Care study (PROSPEC): a randomized controlled trial to evaluate the effectiveness of primary care-based follow-up of localized prostate cancer survivors.
    BMC Cancer. 2020;20:635.
    PubMed     Abstract available


  52. WRIGHT CM, Halkett G, Carey Smith R, Moorin R, et al
    Sarcoma epidemiology and cancer-related hospitalisation in Western Australia from 1982 to 2016: a descriptive study using linked administrative data.
    BMC Cancer. 2020;20:625.
    PubMed     Abstract available


    June 2020
  53. CASARIN S, Dondossola E
    An agent-based model of prostate Cancer bone metastasis progression and response to Radium223.
    BMC Cancer. 2020;20:605.
    PubMed     Abstract available


  54. CHOI JB, Myong JP, Lee Y, Kim I, et al
    Does increased body mass index lead to elevated prostate cancer risk? It depends on waist circumference.
    BMC Cancer. 2020;20:589.
    PubMed     Abstract available


  55. MEHDI A, Cheishvili D, Arakelian A, Bismar TA, et al
    DNA methylation signatures of Prostate Cancer in peripheral T-cells.
    BMC Cancer. 2020;20:588.
    PubMed     Abstract available


  56. KNAUL FM, Doubova SV, Gonzalez Robledo MC, Durstine A, et al
    Self-identity, lived experiences, and challenges of breast, cervical, and prostate cancer survivorship in Mexico: a qualitative study.
    BMC Cancer. 2020;20:577.
    PubMed     Abstract available


  57. BOU-DARGHAM MJ, Sha L, Sang QA, Zhang J, et al
    Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.
    BMC Cancer. 2020;20:572.
    PubMed     Abstract available


  58. LIN E, Garmo H, Van Hemelrijck M, Adolfsson J, et al
    Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study.
    BMC Cancer. 2020;20:551.
    PubMed     Abstract available


  59. LI Q, Shi Y, Sa R, Hao J, et al
    Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression.
    BMC Cancer. 2020;20:555.
    PubMed     Abstract available


  60. HASAN H, Deek MP, Phillips R, Hobbs RF, et al
    A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
    BMC Cancer. 2020;20:492.
    PubMed     Abstract available


    May 2020
  61. NILSSEN Y, Brustugun OT, Eriksen MT, Haug ES, et al
    Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.
    BMC Cancer. 2020;20:488.
    PubMed     Abstract available


  62. MEYER HJ, Wienke A, Surov A
    Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient - a systematic review and meta analysis.
    BMC Cancer. 2020;20:482.
    PubMed     Abstract available


  63. TRAN MGB, Bibby BAS, Yang L, Lo F, et al
    Independence of HIF1a and androgen signaling pathways in prostate cancer.
    BMC Cancer. 2020;20:469.
    PubMed     Abstract available


  64. BERGHEN C, Joniau S, Rans K, Devos G, et al
    Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial.
    BMC Cancer. 2020;20:457.
    PubMed     Abstract available


  65. VUOLUKKA K, Auvinen P, Palmgren JE, Aaltomaa S, et al
    Incidence of subsequent primary cancers and radiation-induced subsequent primary cancers after low dose-rate brachytherapy monotherapy for prostate cancer in long-term follow-up.
    BMC Cancer. 2020;20:453.
    PubMed     Abstract available


  66. DUDKA I, Thysell E, Lundquist K, Antti H, et al
    Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status.
    BMC Cancer. 2020;20:437.
    PubMed     Abstract available


  67. MOORE C, Palau VE, Mahboob R, Lightner J, et al
    Upregulation of pERK and c-JUN by gamma-tocotrienol and not alpha-tocopherol are essential to the differential effect on apoptosis in prostate cancer cells.
    BMC Cancer. 2020;20:428.
    PubMed     Abstract available


  68. QIU C, Bai Y, Yin T, Miao X, et al
    Targeted imaging of orthotopic prostate cancer by using clinical transformable photoacoustic molecular probe.
    BMC Cancer. 2020;20:419.
    PubMed     Abstract available


  69. DE BRUYCKER A, Spiessens A, Dirix P, Koutsouvelis N, et al
    PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
    BMC Cancer. 2020;20:406.
    PubMed     Abstract available


  70. MILLER ET, You S, Cadaneanu RM, Kim M, et al
    Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.
    BMC Cancer. 2020;20:398.
    PubMed     Abstract available


  71. WANG S, Zhou X, Liang C, Bao M, et al
    ALDH1A3 serves as a predictor for castration resistance in prostate cancer patients.
    BMC Cancer. 2020;20:387.
    PubMed     Abstract available


  72. WANG M, Wasserman E, Geyer N, Carroll RM, et al
    Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004-2014.
    BMC Cancer. 2020;20:394.
    PubMed     Abstract available


  73. TAGUCHI S, Uemura Y, Fujimura T, Morikawa T, et al
    Quantification of the individual risk of each Gleason pattern, including tertiary Gleason pattern 5, after radical prostatectomy: development of the modified Gleason grade grouping (mGGG) model.
    BMC Cancer. 2020;20:371.
    PubMed     Abstract available


    April 2020
  74. LI B, Lu Z, Wang S, Hou J, et al
    Pretreatment elevated prognostic nutritional index predicts a favorable prognosis in patients with prostate cancer.
    BMC Cancer. 2020;20:361.
    PubMed     Abstract available


  75. OEHUS AK, Kroeze SGC, Schmidt-Hegemann NS, Vogel MME, et al
    Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    BMC Cancer. 2020;20:362.
    PubMed     Abstract available


  76. ZHENG Z, Zhou Z, Yan W, Zhou Y, et al
    Tumor characteristics, treatments, and survival outcomes in prostate cancer patients with a PSA level < 4 ng/ml: a population-based study.
    BMC Cancer. 2020;20:340.
    PubMed     Abstract available


  77. CHEN JJ, Zhu ZS, Zhu YY, Shi HQ, et al
    Applied anatomy of pelvic lymph nodes and its clinical significance for prostate cancer:a single-center cadaveric study.
    BMC Cancer. 2020;20:330.
    PubMed     Abstract available


  78. LEHTONEN M, Heiskanen L, Reinikainen P, Kellokumpu-Lehtinen PL, et al
    Both comorbidity and worse performance status are associated with poorer overall survival after external beam radiotherapy for prostate cancer.
    BMC Cancer. 2020;20:324.
    PubMed     Abstract available


  79. MATSUDA Y, Narita S, Nara T, Mingguo H, et al
    Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer.
    BMC Cancer. 2020;20:302.
    PubMed     Abstract available


  80. CHEN C, Cai Z, Zhuo Y, Xi M, et al
    Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
    BMC Cancer. 2020;20:289.
    PubMed     Abstract available


    March 2020
  81. SIMMONS AD, Nguyen M, Pintus E
    Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
    BMC Cancer. 2020;20:215.
    PubMed     Abstract available


    January 2020
  82. NAWAS AF, Kanchwala M, Thomas-Jardin SE, Dahl H, et al
    IL-1-conferred gene expression pattern in ERalpha(+) BCa and AR(+) PCa cells is intrinsic to ERalpha(-) BCa and AR(-) PCa cells and promotes cell survival.
    BMC Cancer. 2020;20:46.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: